サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747772

A型肝炎ワクチンの世界市場

Hepatitis A Vaccines

出版日
ページ情報
英文 282 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.42円
A型肝炎ワクチンの世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 282 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

A型肝炎ワクチンの世界市場は2030年までに8億9,140万米ドルに達する見込み

2024年に7億8,470万米ドルと推定されるA型肝炎ワクチンの世界市場は、分析期間2024-2030年にCAGR 2.1%で成長し、2030年には8億9,140万米ドルに達すると予測されます。本レポートで分析したセグメントのひとつである不活化ワクチンは、CAGR 1.6%を記録し、分析期間終了時には5億7,250万米ドルに達すると予測されます。生ワクチン分野の成長率は、分析期間中CAGR 3.1%と推定されます。

米国市場は2億1,380万米ドルと推定、中国はCAGR 4.1％で成長予測

米国のA型肝炎ワクチン市場は、2024年に2億1,380万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億6,790万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8%と1.6%と予測されています。欧州では、ドイツがCAGR 1.1%で成長すると予測されています。

世界のA型肝炎ワクチン市場- 主要動向と促進要因まとめ

なぜA型肝炎ワクチン接種は世界の公衆衛生の優先事項であり続けるのか？

A型肝炎ウイルス（HAV）によって引き起こされる急性肝臓感染症であるA型肝炎は、衛生環境が悪く、清潔な水へのアクセスが不十分な地域において、依然として大きな脅威となっています。A型肝炎ウイルスは主に糞口経路で感染し、感染力が非常に強いため、特に開発途上諸国や、小児、旅行者、混雑した環境にいる人々など、感染しやすい人々の間で大流行しています。A型肝炎はほとんどの場合自己治癒するが、特に高齢者や免疫不全者では劇症肝不全を引き起こすことがあります。

A型肝炎感染を予防する最も効果的な方法は、依然としてワクチン接種です。小児、旅行者、軍人、食品取扱者、ヘルスケア従事者を対象とした世界の予防接種プログラムにより、リスクの高い地域での発症率は著しく低下しています。開発途上国でも先進国でも、衛生状態の悪化、気候に起因する水質汚染、海外旅行などが原因で、局地的な集団感染が頻発していることから、持続的な予防接種活動の重要性が強調されています。小児期の普遍的な予防接種と流行への対応戦略は、長期的な疾病管理の重要な柱です。

ワクチン製剤とデリバリー・プラットフォームはどのように進化しているのか？

A型肝炎ワクチンは、長期的な免疫のために2回接種される不活化ワクチン（殺ウイルスワクチン）です。新しい進歩として、A型肝炎とB型肝炎や腸チフスなどの他の抗原を統合した混合ワクチンが研究されており、注射の回数を減らし、コンプライアンスを向上させています。小児に特化した製剤や、集団発生時の緊急用単回投与レジメンも開発されており、接種率や利用しやすさが向上しています。

コールドチェーン安定性、注射針を使用しない送達システム、アジュバント技術の向上により、遠隔地や資源が限られた環境でのワクチンの使用可能性が拡大しています。冷蔵しなくても効力を維持できる耐熱性製剤の開発も進められており、これは熱帯地域でのアウトリーチ拡大には不可欠な機能です。また、予防接種記録の追跡や流行ホットスポットの予測にデジタルヘルスツールを採用することで、公衆衛生の展開と予防接種範囲の最適化戦略が強化されています。

予防接種需要を牽引している地域と人口区分は？

アジア太平洋、ラテンアメリカ、アフリカ、中東の流行地域は、A型肝炎ワクチンの最大市場であり、特に農村部や十分なサービスを受けていない地域で顕著です。インド、中国、インドネシア、ブラジルのような国々では、国際保健機関の支援を受けて、大規模な予防接種キャンペーンが実施されています。先進国では、主に海外からの旅行者、男性と性交渉を持つ男性（MSM）、ホームレス経験者、食品産業従事者など、リスクの高いグループを対象に予防接種が行われています。

観光業や労働力の移動も、A型肝炎が旅行関連疾患とみなされるようになった非流行地域でのワクチン接種を後押しする重要な要因です。多くの国の教育部門や軍事組織は、共同生活環境を守るためにA型肝炎の予防接種を制度化しています。米国、イスラエル、オーストラリアなどの国々では、小児科の定期予防接種プログラムによって罹患率の低下に成功しており、世界の政策の調和に影響を及ぼしています。

A型肝炎ワクチン市場の成長は複数の要因によってもたらされる

A型肝炎ワクチン市場の成長は、アウトブレイクの発生率の増加、定期予防接種プログラムの拡大、旅行関連の健康リスクの世界の増加によってもたらされます。先進諸国では、人口移動、都市部の混雑、十分なサービスを受けていない地域の不衛生などが原因でA型肝炎が再燃しており、成人向けおよびキャッチアップ型の予防接種プログラムに再び重点が置かれています。政府が支援する保健キャンペーン、国際援助資金、就学時ワクチン接種の義務化により、流行地域でも非流行地域でも接種率が高まっています。

ワクチン製剤、多抗原混合ワクチン、耐熱性保管ソリューションの技術的改善により、特に低資源環境において、市場へのアクセスが向上しています。さらに、食中毒や水系感染症に対する意識の高まり、特定の労働者に対する雇用主によるワクチン接種の義務付け、アウトブレイクサーベイランスの向上などがワクチン需要を支えています。世界の医療制度が予防医療と国境を越えた疾病管理を重視する中、A型肝炎ワクチン市場は持続的かつ多様な地理的成長を遂げる位置にあります。

セグメント

タイプ（不活化ワクチン,活性化ワクチン）;用途（政府機関,民間セクター,その他用途）

調査対象企業の例（全48件）

  • Bharat Biotech
  • Biological E. Limited
  • Chiron Behring Vaccines
  • Crucell（a Janssen Pharmaceutical Company）
  • GlaxoSmithKline plc
  • Indian Immunologicals Limited
  • LG Chem
  • Merck & Co., Inc.
  • Panacea Biotec
  • Pukang Biotech
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shanta Biotechnics
  • Sinovac Biotech Ltd.
  • SK Bioscience
  • Takeda Pharmaceutical Company Limited
  • VBI Vaccines Inc.
  • Walvax Biotechnology Co., Ltd.
  • Zydus Lifesciences Limited
  • Zydus Vaccines

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35168

Global Hepatitis A Vaccines Market to Reach US$891.4 Million by 2030

The global market for Hepatitis A Vaccines estimated at US$784.7 Million in the year 2024, is expected to reach US$891.4 Million by 2030, growing at a CAGR of 2.1% over the analysis period 2024-2030. Inactivated Vaccine, one of the segments analyzed in the report, is expected to record a 1.6% CAGR and reach US$572.5 Million by the end of the analysis period. Growth in the Live Attenuated Vaccine segment is estimated at 3.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$213.8 Million While China is Forecast to Grow at 4.1% CAGR

The Hepatitis A Vaccines market in the U.S. is estimated at US$213.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$167.9 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Hepatitis A Vaccines Market - Key Trends & Drivers Summarized

Why Does Hepatitis A Vaccination Remain a Global Public Health Priority?

Hepatitis A, an acute liver infection caused by the Hepatitis A virus (HAV), continues to pose a significant threat in regions with poor sanitation and inadequate access to clean water. The virus spreads primarily through the fecal-oral route and is highly contagious, leading to outbreaks particularly in developing countries and among vulnerable populations such as children, travelers, and people in crowded settings. Although self-limiting in most cases, Hepatitis A can lead to fulminant hepatic failure, particularly in older adults and immunocompromised individuals.

Vaccination remains the most effective method of preventing Hepatitis A infection. Global immunization programs targeting children, travelers, military personnel, food handlers, and healthcare workers have significantly reduced incidence rates in high-risk areas. The increasing frequency of localized outbreaks in both developing and developed nations-often driven by poor hygiene, climate-related water contamination, or international travel-continues to underline the importance of sustained vaccination efforts. Universal childhood immunization and outbreak response strategies are key pillars of long-term disease control.

How Are Vaccine Formulations and Delivery Platforms Evolving?

Hepatitis A vaccines are traditionally inactivated (killed virus) formulations administered in two doses for long-term immunity. Newer advancements are exploring combination vaccines that integrate Hepatitis A with other antigens such as Hepatitis B or typhoid, reducing the number of injections and improving compliance. Pediatric-specific formulations and single-dose regimens for emergency use during outbreaks are being developed to enhance coverage and accessibility.

Improved cold-chain stability, needle-free delivery systems, and adjuvant technologies are expanding vaccine usability in remote or resource-limited settings. Efforts are underway to develop thermostable formulations that maintain potency without refrigeration-an essential feature for expanding outreach in tropical regions. The adoption of digital health tools for tracking immunization records and predicting outbreak hotspots is also enhancing public health deployment and coverage optimization strategies.

Which Regions and Population Segments Are Driving Vaccination Demand?

Endemic regions in Asia-Pacific, Latin America, Africa, and the Middle East represent the largest markets for Hepatitis A vaccines, particularly in rural and underserved areas. Mass immunization campaigns, often supported by global health agencies, are underway in countries like India, China, Indonesia, and Brazil. In developed nations, vaccination is primarily targeted at high-risk groups including international travelers, men who have sex with men (MSM), people experiencing homelessness, and food industry workers.

Tourism and labor migration are also key factors boosting vaccine uptake in non-endemic regions, where Hepatitis A is now considered a travel-associated disease. The education sector and military organizations in many countries are institutionalizing Hepatitis A immunization to protect communal living environments. Routine pediatric immunization programs in countries such as the U.S., Israel, and Australia have successfully reduced incidence rates and are influencing global policy harmonization.

The Growth in the Hepatitis A Vaccines Market Is Driven by Several Factors

The growth in the Hepatitis A vaccines market is driven by increasing incidence of outbreaks, expansion of routine immunization programs, and the global rise in travel-related health risks. The resurgence of Hepatitis A in developed countries due to population movement, urban crowding, and poor hygiene in underserved communities is prompting renewed emphasis on adult and catch-up vaccination programs. Government-backed health campaigns, international aid funding, and school-entry vaccine mandates are amplifying coverage in both endemic and non-endemic regions.

Technological improvements in vaccine formulation, multi-antigen combinations, and thermostable storage solutions are enhancing market accessibility, especially in low-resource settings. Additionally, greater awareness of foodborne and waterborne diseases, employer-mandated vaccinations for specific workforces, and better outbreak surveillance are supporting vaccine demand. As global health systems emphasize preventive care and cross-border disease control, the Hepatitis A vaccine market is positioned for sustained, geographically diverse growth

SCOPE OF STUDY:

The report analyzes the Hepatitis A Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Inactivated Vaccine, Live Attenuated Vaccine); Application (Government Institution, Private Sector, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Bharat Biotech
  • Biological E. Limited
  • Chiron Behring Vaccines
  • Crucell (a Janssen Pharmaceutical Company)
  • GlaxoSmithKline plc
  • Indian Immunologicals Limited
  • LG Chem
  • Merck & Co., Inc.
  • Panacea Biotec
  • Pukang Biotech
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shanta Biotechnics
  • Sinovac Biotech Ltd.
  • SK Bioscience
  • Takeda Pharmaceutical Company Limited
  • VBI Vaccines Inc.
  • Walvax Biotechnology Co., Ltd.
  • Zydus Lifesciences Limited
  • Zydus Vaccines

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Hepatitis A Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Awareness of Vaccine-Preventable Diseases Drives Uptake of Hepatitis A Vaccination Programs
    • Increasing Incidence of Hepatitis A Outbreaks in Low-to-Middle-Income Regions Spurs Mass Immunization Campaigns
    • Inclusion of Hepatitis A Vaccines in National Immunization Schedules Expands Access and Public Sector Procurement
    • Growth in International Travel and Tourism Encourages Preventive Vaccination Among High-Risk Populations
    • Expansion of Pediatric Vaccination Coverage Globally Supports Early Immunization Against Hepatitis A
    • Combination Vaccines Featuring Hepatitis A and B Enhance Compliance and Broaden Market Reach
    • Support From Global Health Agencies and NGOs Strengthens Funding for Vaccination in Endemic Areas
    • Advancements in Cold Chain Infrastructure Improve Vaccine Distribution in Remote and Underserved Locations
    • Rising Demand for Adult and Occupational Vaccination Fuels Non-Pediatric Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hepatitis A Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hepatitis A Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Hepatitis A Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Inactivated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Inactivated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Live Attenuated Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Live Attenuated Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Government Institution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Government Institution by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Government Institution by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Private Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Private Sector by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Private Sector by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Hepatitis A Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Hepatitis A Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Hepatitis A Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Hepatitis A Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • INDIA
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Hepatitis A Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Hepatitis A Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Hepatitis A Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Hepatitis A Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030
  • AFRICA
    • Hepatitis A Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Hepatitis A Vaccines by Type - Inactivated Vaccine and Live Attenuated Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Hepatitis A Vaccines by Type - Percentage Breakdown of Value Sales for Inactivated Vaccine and Live Attenuated Vaccine for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Hepatitis A Vaccines by Application - Government Institution, Private Sector and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Hepatitis A Vaccines by Application - Percentage Breakdown of Value Sales for Government Institution, Private Sector and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION